ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giraldo, A.
Right arrow Articles by Humes, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giraldo, A.
Right arrow Articles by Humes, J.
Annals of Clinical and Laboratory Science, Vol 13, Issue 4, 307-314
Copyright © 1983 by Association of Clinical Scientists


Articles

Blood group antigens in urothelium in transitional cell carcinoma

AA Giraldo, SG Ruby, and JJ Humes

A study is reported relating clinical behavior of transitional cell carcinoma of the urinary bladder to blood group substance expression on the surface urothelium using an immunoperoxidase technique. Eighty-seven biopsies from 60 patients were studied. An average follow-up of 84.7 months was obtained. Blood group substance was detected in 61 percent of low grade (I) tumors and in 41 percent of high grade (II to III) tumors. Low grade (I) tumors which exhibited the blood group substance followed a benign clinical course in 70 percent of the cases and an aggressive clinical course in 30 percent. The high grade (II to III) tumors which exhibited blood group substance followed a more benign clinical course in 54 percent of the cases whereas behavior was clinically aggressive in 46 percent. It is concluded that the presence of blood group substance on urothelial malignancies, although appearing to correlate in some degree with the aggressiveness of the disease, is not statistically significant in all tumor grades and is not an absolute finding that can be clinically used in a prospective manner to determine prognosis and treatment for the individual patient. The expression of this antigen does not appear to be statistically significant in low grade (I) lesions as previously reported; however, it may play a more important role in considering higher grade (II to III) lesions.


This article has been cited by other articles:


Home page
Clin. Chem.Home page
E. M. Vestergaard, H. Wolf, and T. F. Orntoft
Increased concentrations of genotype-interpreted Ca 19-9 in urine of bladder cancer patients mark diffuse atypia of the urothelium
Clin. Chem., February 1, 1998; 44(2): 197 - 204.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by the Association of Clinical Scientists.